Articles Safety and immunogenicity of a vaccine for extraintestinal pathogenic Escherichia coli ESTELLA a phase 2 randomised controlled trial

[Articles] Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial

20:45 EDT 9 May 2019 | The Lancet

EXPEC4V seemed well tolerated and elicited robust and functional antibody responses across all serotypes, doses, and age groups. For the two dosages evaluated (4:4:4:8 μg and 8:8:8:16 μg), the immune response persisted for 1 year.

More From BioPortfolio on "[Articles] Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial"